FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab.

Cosman, Felicia

FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab. [electronic resource] - Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 07 2018 - 1219-1226 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1523-4681

10.1002/jbmr.3427 doi


Aged
Antibodies, Monoclonal--therapeutic use
Bone Density
Denosumab--therapeutic use
Fractures, Bone--epidemiology
Humans
Osteogenesis
Risk Factors